




RealRate

PHARMACEUTICAL 2020

Enveric Biosciences Inc
Rank 207 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Enveric Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enveric Biosciences Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Enveric Biosciences Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 158% points.

The company's Economic Capital Ratio, given in the ranking table, is 221%, being 17% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	7,599
Cost of Goods Sold	31,764
Intangible Assets	17,314
Liabilities, Current	14,384
Liabilities, Non-Current	0
Other Assets	8.9
Other Compr. Net Income	-453
Other Expenses	2,654
Other Liabilities	0
Other Net Income	1,110
Other Revenues	39,915
Property and Equipment	83
Research and Development	0
Selling, General and Administrative Expense	12,210

Output Variable	Value in 1000 USD
Assets	25,005
Liabilities	14,384
Expenses	46,628
Revenues	39,915
Stockholders Equity	10,622
Net Income	-5,604
Comprehensive Net Income	-5,830
BaseVar	63,747
ECR before Limited Liability	88%
Economic Capital Ratio	221%